News | December 20, 2022
Ipca acquires further 6.53% of equity share of Trophic Wellness
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
The product is backed by required scientific proof and comparative bioequivalence studies
Post the sale, Patel family has become the single largest promoter shareholder in the company
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The investment will enable the company to enter European markets as well as enhance margins in current markets
Sanjeev is currently the Country President for AstraZeneca Malaysia
He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
Subscribe To Our Newsletter & Stay Updated
